Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Boehringer Ingelheim
Biotech
Boehringer slots synthetic lethal program into oncology pipeline
Boehringer has partnered with Tessellate Bio on a synthetic lethal program in a deal worth more than 500 million euros in biobucks.
Nick Paul Taylor
Apr 23, 2025 7:45am
Boehringer lines up B-cell depletion autoimmune R&D via Cue deal
Apr 15, 2025 4:45am
German program matches lost NIH grants with pharma funders
Apr 7, 2025 10:50am
Boehringer commits $31M to ADC R&D via NBE Therapeutics facility
Apr 3, 2025 5:30am
Sotio takes up option on ADCs, Boehringer inks discovery pact
Mar 13, 2025 10:53am
Boehringer Ingelheim launches new R&D platform One Medicine
Mar 12, 2025 5:50am
